Kaifeng Qiu

1.1k total citations
32 papers, 860 citations indexed

About

Kaifeng Qiu is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Kaifeng Qiu has authored 32 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Kaifeng Qiu's work include Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Kaifeng Qiu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). Kaifeng Qiu collaborates with scholars based in China, United States and Switzerland. Kaifeng Qiu's co-authors include Mingyi Li, Ying Liang, Guocheng Li, Chuxiong Chen, Junyan Wu, Zhichao He, Jianhong Zhu, Yayuan Zheng, Xiaobin Zheng and Cuiju Wen and has published in prestigious journals such as FEBS Letters, British Journal of Pharmacology and Thorax.

In The Last Decade

Kaifeng Qiu

30 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaifeng Qiu China 13 340 222 161 117 111 32 860
Jing Huang China 17 559 1.6× 219 1.0× 276 1.7× 105 0.9× 64 0.6× 78 1.3k
Qiang Zhao China 16 454 1.3× 252 1.1× 67 0.4× 37 0.3× 53 0.5× 58 918
Naoki Nanashima Japan 18 295 0.9× 109 0.5× 125 0.8× 28 0.2× 63 0.6× 51 933
Zhidong Wang China 23 678 2.0× 207 0.9× 248 1.5× 43 0.4× 33 0.3× 78 1.4k
Maria Principia Scavo Italy 19 394 1.2× 182 0.8× 89 0.6× 41 0.4× 66 0.6× 57 877
Raffaele Di Francia Italy 20 337 1.0× 129 0.6× 363 2.3× 42 0.4× 32 0.3× 66 1.1k
Rajinder Singh United Kingdom 20 402 1.2× 191 0.9× 301 1.9× 23 0.2× 35 0.3× 35 1.4k
Chiara Focaccetti Italy 19 491 1.4× 222 1.0× 485 3.0× 25 0.2× 48 0.4× 41 1.4k

Countries citing papers authored by Kaifeng Qiu

Since Specialization
Citations

This map shows the geographic impact of Kaifeng Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaifeng Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaifeng Qiu more than expected).

Fields of papers citing papers by Kaifeng Qiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaifeng Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaifeng Qiu. The network helps show where Kaifeng Qiu may publish in the future.

Co-authorship network of co-authors of Kaifeng Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaifeng Qiu. A scholar is included among the top collaborators of Kaifeng Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaifeng Qiu. Kaifeng Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Yijia, et al.. (2024). Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer. Immunotherapy. 16(10). 669–678. 2 indexed citations
2.
Liu, Xiaolin, Ying Wang, Kaifeng Qiu, et al.. (2024). Physiologically-based pharmacokinetic modelling to investigate the effect of CYP3A4/3A5 maturation on tacrolimus pharmacokinetics in paediatric HSCT patients. European Journal of Pharmaceutical Sciences. 201. 106839–106839.
3.
Zhu, Jianhong, Jianfang Li, Yayuan Zheng, et al.. (2023). Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology. 125(Pt B). 111184–111184. 2 indexed citations
4.
He, Zhichao, Wei Jiang, Jianhong Zhu, et al.. (2023). Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database. International Journal of Gynecological Cancer. 33(8). 1237–1246. 1 indexed citations
5.
Zhu, Jianhong, Dan Liang, Yayuan Zheng, et al.. (2022). Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology. 110. 109053–109053. 5 indexed citations
6.
He, Zhichao, Wenxia Zhao, Shan Yang, et al.. (2022). SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetologica. 60(3). 401–411. 18 indexed citations
7.
Wang, Ying, Jian Wang, Kaifeng Qiu, et al.. (2022). Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients. Frontiers in Pharmacology. 13. 891648–891648. 5 indexed citations
8.
Chen, Zepeng, Ming Li, Shuzhen Li, et al.. (2022). A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. Expert Opinion on Drug Safety. 22(4). 339–342. 6 indexed citations
9.
Wang, Ying, Dan Liang, Hua Zhu, et al.. (2020). Developing an Isotope Dilution UHPLC–MS/MS Method to Quantify Linezolid in Human Plasma: Application to Therapeutic Drug Monitoring. Bioanalysis. 12(14). 991–1001. 5 indexed citations
10.
Zhang, Mei, Jianhong Zhu, Zhichao He, et al.. (2020). Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 19(5). 617–623. 7 indexed citations
11.
Zhu, Jianhong, Yayuan Zheng, Jianfang Li, et al.. (2020). Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. The Lancet Diabetes & Endocrinology. 8(3). 192–205. 106 indexed citations
12.
Xu, Ying, Rui Ding, Kaifeng Qiu, et al.. (2019). Extensive serum biomarker analysis in patients with non-small-cell lung carcinoma. Cytokine. 126. 154868–154868. 23 indexed citations
13.
Zhu, Jianhong, Wenxia Zhao, Dan Liang, et al.. (2017). Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. International Journal of Clinical Oncology. 23(2). 389–399. 1 indexed citations
14.
Zhu, Jianhong, Junyan Wu, Guocheng Li, et al.. (2017). Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opinion on Drug Safety. 16(4). 423–428. 8 indexed citations
15.
16.
Huang, Feifei, Liu Yang, Xia Yang, et al.. (2017). Shexiang Baoxin pills promotes angiogenesis in myocardial infarction rats via up-regulation of 20-HETE-mediated endothelial progenitor cells mobilization. Atherosclerosis. 263. 184–191. 30 indexed citations
17.
Liao, Rifang, et al.. (2017). Insulin‐like growth factor‐1 activates PI3K/Akt signalling to protect human retinal pigment epithelial cells from amiodarone‐induced oxidative injury. British Journal of Pharmacology. 175(1). 125–139. 25 indexed citations
18.
Qiu, Kaifeng, et al.. (2016). miR-22 regulates cell invasion, migration and proliferation in vitro through inhibiting CD147 expression in tongue squamous cell carcinoma. Archives of Oral Biology. 66. 92–97. 27 indexed citations
19.
20.
Zhang, Kun-Shui, Huiqing Chen, Kaifeng Qiu, et al.. (2014). Bisphenol A stimulates human lung cancer cell migration via upregulation of matrix metalloproteinases by GPER/EGFR/ERK1/2 signal pathway. Biomedicine & Pharmacotherapy. 68(8). 1037–1043. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jing Huang Breakdown of academic impact, for papers by Qiang Zhao Breakdown of academic impact, for papers by Naoki Nanashima Breakdown of academic impact, for papers by Zhidong Wang Breakdown of academic impact, for papers by Maria Principia Scavo Breakdown of academic impact, for papers by Raffaele Di Francia Breakdown of academic impact, for papers by Rajinder Singh Breakdown of academic impact, for papers by Chiara Focaccetti
Rankless by CCL
2026